Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.
2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly..

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.
4.

Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.

Masand PS, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, Rasgon N.

CNS Spectr. 2005 Oct;10(10):suppl14 1-15.

PMID:
16404802
5.
6.

Primary care issues in patients with mental illness.

Kiraly B, Gunning K, Leiser J.

Am Fam Physician. 2008 Aug 1;78(3):355-62.

7.

Schizophrenia and comorbid metabolic disorders.

Henderson DC.

J Clin Psychiatry. 2005;66 Suppl 6:11-20. Review.

8.

Antipsychotic medications: metabolic and cardiovascular risk.

Newcomer JW.

J Clin Psychiatry. 2007;68 Suppl 4:8-13. Review.

9.

[Brazilian Consensus on second-generation antipsychotics and metabolic disorders].

Elkis H, Gama C, Suplicy H, Tambascia M, Bressan R, Lyra R, Cavalcante S, Minicucci W.

Rev Bras Psiquiatr. 2008 Mar;30(1):77-85. Portuguese.

10.

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.

De Hert M, van Eyck D, De Nayer A.

Int Clin Psychopharmacol. 2006 Mar;21 Suppl 2:S11-5. Review.

PMID:
16601508
11.

Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness.

Vergara-Rodriguez P, Vibhakar S, Watts J.

Pharmacol Ther. 2009 Dec;124(3):269-78. doi: 10.1016/j.pharmthera.2009.07.004. Epub 2009 Jul 30. Review.

PMID:
19647020
12.

Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

Casey DE.

Am J Med. 2005 Apr;118 Suppl 2:15S-22S. Review.

PMID:
15903291
13.

[Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview].

Scheepers-Hoeks AM, Wessels-Basten SJ, Scherders MJ, Bravenboer B, Loonen AJ, Kleppe RT, Grouls RJ.

Tijdschr Psychiatr. 2008;50(10):645-54. Review. Dutch.

14.
15.
16.
17.
18.

Balancing efficacy and safety in treatment with antipsychotics.

Correll CU.

CNS Spectr. 2007 Oct;12(10 Suppl 17):12-20, 35. Review.

PMID:
17934385
19.

Treating the mind and body in schizophrenia: risks and prevention.

Meyer JM.

CNS Spectr. 2004 Oct;9(10 Suppl 11):25-33.

PMID:
15475874
20.

Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.

Wheeler AJ.

Ann Pharmacother. 2008 Jun;42(6):852-60. doi: 10.1345/aph.1K662. Epub 2008 May 13.

PMID:
18477732

Supplemental Content

Support Center